Navigation Links
Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
Date:11/4/2014

NEW YORK, Nov. 4, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.

Mr. Becker brings more than 20 years of experience as a C-level industry executive and Wall Street securities analyst. Most recently, he was founder and president of the consulting firm MDB Communications LLC. In this position, he acted as a strategic advisor and partner servicing the life sciences industry by providing a full range of investor relations and public relations services to enhance client visibility and branding. 

"We are very pleased to have Michael joining us as senior vice president of finance and corporate development," said Sergio Traversa, CEO of Relmada. "He brings strong financial leadership and a wealth of industry experience to the company and is well-suited to lead our corporate development efforts during the continued evolution of Relmada. As a key member of our leadership team, Michael will be a tremendous asset as we approach planned clinical milestones and prepare to apply for uplisting on the NASDAQ Capital Market as soon as feasable."

Mr. Becker previously served as president, chief executive officer, and member of the board of directors for publicly traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma). He held positions of increasing responsibility prior to being appointed president and CEO of Cytogen in 2002, including vice president of business development, industry and investor relations and CEO of AxCell Biosciences, a subsidiary of Cytogen. Prior to his industry career, Mr. Becker spent 9 years in the financial services industry, which includes positions at Wayne Hummer Investments LLC, Kidder, Peabody & Co., Gruntal & Co., and Kemper Securities. He completed coursework in Political Science at DePaul University and received an Associate of Science degree from the Art Institute of Pittsburgh.

"I am very excited to join the Relmada team," said Mr. Becker. "With a strong balance sheet, impressive scientific expertise, and ambitious strategy, I see tremendous potential for the Company and its diverse pipeline of pain treatment products. I look forward to working with the Relmada team to realize the full potential of this dynamic platform."

About Relmada Therapeutics Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain.  The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com

Forward-Looking Statements

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact

Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169
mbecker@relmada.com


'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants
2. Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
3. Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
4. Relmada Announces The Filing Of Clinical Trial Application In Canada For d-methadone
5. Relmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company
6. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
7. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
8. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
9. Relmada Therapeutics Announces LevoCap ER Development Progress
10. Pain Therapeutics - Drugs, Markets and Companies
11. Echo Therapeutics to Present Positive Clinical Trial Results at the 14th Annual Diabetes Technology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... , ... October 10, 2019 , ... This World Sight ... Living with kathy ireland® is pleased to announce their recent interview with Brand ... showcasing how they help consumers of all abilities identify and choose effective hair care ...
(Date:10/8/2019)... ... , ... Help.org, a trusted online resource for individuals who struggle with addiction ... 2019. The informational guide recognizes the top 17 rehab facilities based on cost, treatment ... drug overdose is the leading cause of death among people under age 50. In ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... in an advanced dental implant seminar to enhance his skill and knowledge of ... The Implant Dentistry Continuum™ is a four-part series of classes that combines in-depth ...
Breaking Medicine Technology:
(Date:10/8/2019)... PARK, Md. (PRWEB) , ... October 08, 2019 ... ... observe fungal infection progression in live samples, Meiqing Shi, associate professor with the ... the field. In his latest paper published in Nature Communications, Shi and his ...
(Date:10/8/2019)... ... October 08, 2019 , ... Smile Brands Inc. has been named one ... Comparably. Smile Brands, a leading dental support organization with nearly 440 affiliated practices across ... Smiles for Everyone®. The Happiness Award is the latest in a series of ...
(Date:10/8/2019)... ... 08, 2019 , ... Fewer than 50 percent of preclinical ... Rigor in bioanalytical method validation is emerging in the form of a global ... the time) and senior scientists add the management of an offshore team to ...
(Date:10/8/2019)... ... October 08, 2019 , ... symplr®, a leading healthcare ... integration between the IntelliCredTM cre-dentialing software suite and the SkillSurvey® digital peer referencing ... obtain peer refer-ences and affiliations to less than three days. , “Through this ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... to dentists, is pleased to announce the addition of Brenda Thomas, an industry ... is an Account Manager for the Professional Services Plans dental team at Brown ...
Breaking Medicine News(10 mins):